Maker of Wegovy, Ozempic Showers Money on U.S. Obesity Doctors

December 1, 2023

A picture of a slide adjusting scale

(Reuters) – Drugmaker Novo Nordisk paid U.S. medical professionals at least $25.8 million over a decade in fees and expenses related to its weight-loss drugs, a Reuters analysis found. It concentrated that money on an elite group of obesity specialists who advocate giving its powerful and expensive drugs to tens of millions of Americans. (Read More)